Mary Kay Inc., through its Mary Kay Ash Foundation, is supporting a groundbreaking initiative that aims to revolutionize early detection and intervention strategies for breast cancer. The foundation’s generous grant is funding the TRIM-EBC Trial (Tirzepatide weight loss in patients with MRD and Early Breast Cancer) in alignment with Baylor Scott & White Health and the Texas Cancer Interception Institute (TCII). Led by Joyce O’Shaughnessy, MD, the study investigates whether weight loss through tirzepatide could reduce breast cancer occurrence by lowering or eliminating circulating tumor DNA.
The Mary Kay Ash Foundation’s donations to these efforts are part of its long-term commitment to advance the critical work of reducing the risk of breast cancer and finding cures for cancers affecting women, and reflects its dedication to shaping the future of cancer interception and prevention strategies.
Dr. O’Shaughnessy is a key player in the TRIM-EBC Trial and was honored as one of the nation’s leading breast oncologists at the 2025 Celebrating Women Luncheon, where the Mary Kay Ash Foundation was also honored with the prestigious Circle of Care Award.
“When I started more than 35 years ago, there were no senior women faculty at my institution – none,” Dr. O’Shaughnessy said. “The opportunities just weren’t there. That has changed dramatically. Once women began moving into leadership roles and succeeding, it created a snowball effect. Seeing women in those positions makes others realize it’s possible. That visibility is critical – not just for women in general, but also for minority women. You need to see someone like yourself doing the job to believe you can do it too.”
The post Mary Kay Ash Foundation Grant Supports Revolutionary Breast Cancer Research first appeared on Direct Selling News.
